Effect of 8-Chloroadenosine on Undifferentiatied HL-60 Cell Line

Abstract

Abstract: Aim To study the effect of 8-chloroadenosine (8-CA)on undifferentiatied HL-60 cell line. Methods The IC50 of cancer cell proliferation was determined using a microculture plate reader at 570 nm (MTT) and 540 nm (SRB). Morphology of HL-60 cells was observed under a scanning electron microscope and a transmission electron microscope. The differentiation of HL-60 cells was examined by nitro blue tetrazolium reduction (NBT) and acid phosphatase assay. The cy-cle of HL-60 cells was analyzed by flow cytometry. Results 8-CA inhibited proliferation of eight human cancer cell lines.The IC50 ranked in the following order: KB (0.05μmol·L^-1)<HL-60(0.25 μmol·L^-1)<Bel-7402(0.56μmol·L^-1)<MCF(0.65μmol·L^-1)<HCT(0.79μmol·L^-1)<Hela(0.89μmol·L^-1)<BGC-823(1.49μmol·L^-1)<PG(2.50μmol·L^-1). The scanning and transmission electron microscopy showed that the microvilli of HL-60 cell surface shortened, and the shape of HL-60 cells nuclei changed to kidney-shaped, horse shoe-shaped and bilob ated after treatment with 8-CA. Meanwhile, 8-CA promoted NBT reduction and increased activity of acid phosphatase in HL-60 cells in a time and concentration-dependent manner. Flow cytometry analysis indicated that 8-CA induced an appreciable increase of the cell population in G1 phase with a marked reduction in S phase. Conclusion 8-CA can induce differentiation of HL-60 cells and block the cells at G1 phase, thus inhibiting proliferation of HL-60 cells.

Key words: 8-chloroadenosine, 8-chloroadenosine, HL-60 cell line, HL-60 cell line, differentiation, differentiation, cell cycle, cell cycle

CLC Number:

R965.2

R979.1

Supporting:

CUI Jing-rong, HUI Yu, XIANG You-qing, ZHANG Li-he^*. Effect of 8-Chloroadenosine on Undifferentiatied HL-60 Cell Line[J]. .

References

[1] Pastan I, Johnson GS, Anderson WB. Role of cyclic nucleotides in growth control [J]. Annu Rev Biochem, 1975, 44: 491-522.
[2] Cho-Chung YS. Hypothesis, cyclic AMP and its receptor protein in tumor growth regulation in vivo [J]. J Cyclic Nucleotide Res, 1980, 6: 163-177.
[3] Propper DJ, SaundersMP, Salisbury AJ, et al. Phase I study of the novel cyclic AMP (cAMP) analogue, 8-chloro-cAMP, in patient with cancer: toxicity, hormonal, and immunological effects [J]. Clin Cancer Res, 1999, 5 (7): 1682-1689.
[4] Tortora G, Ciardiello F, Pepe S, et al. Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients [J]. Clin Cancer Res, 1995, 1: 377-384.
[5] Bosanquet AG, Bulton AR, Bell PB, et al. Ex vivo cytotoxic drug evaluation by DISC assay to expedite identification of clinical targets: results with 8-chloro-cAMP [J]. Br J Cancer, 1997, 76 (4): 511-518.
[6] Mcdaid HM, Johnston PG. Synergistic interaction between paclitaxel and 8-chloro-cAMP in human ovarian carcinoma cell lines [J]. Clin Cancer Res, 1999, 5 (1): 215-220.
[7] Schwede F, Masonde E, Genieser HG, et al. Cyclic nucleotide analogs as biochemical tools and prospective drugs [J]. Pharmacol Ther, 2000, 87: 199-226.
[8] Pierosandro T, Dionyssios K, Timothy C, et al. Synergistic inhibition of growth of breast and colon human cancer cell lines site-selective cyclic AMP analogues [J]. Cancer Res,1988, 48 (6): 1642-1650.
[9] Hoffmanun C, Raffel S, Ruchaud S, et al. Chloro-substituted cAMP analogues and their adenosine metabolites induce apoptosis of the human promyelocytic leukemia cell line NB4: molecular basis for cell type selectivity [J]. Cell Pharmacol,1996, 3: 417-427.
[10] Van L, Campagne MM, Villalba DF, et al. 8-Chloroadenosine 3’,5’- monophosphate inhibits the growth of Chinese hamster ovary and Molt-4 cells through its adenosine metabolite [J]. Cancer Res, 1991, 51 (6): 1600-1605.
[11] Cornelis HL, Cornelis AM, Jongenelen JJ, et al. Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3’,5’-mono-phosphate [J]. Cancer Res, 1992, 52 (14): 3994-3999.
[12] Cho-Chung YS. Commentary: site-selective 8-chloro-cyclic adenosine 3’,5’-monophosphate as a biologic modulator of cancer: restoration of normal control mechanisms [J]. J Natl Cancer Inst, 1989, 81: 982-987.
[13] Fang JC, Shi YJ, Peng J, et al. Antitumor activities of 8-chloroadenosine in vivo and in vitro [J]. Chin J Clin Oncol,1995, 17 (1): 5-8.
[14] Yan JH, Fang JC, Shi YJ, et al. Effects of 8-chloroadenosine on murine hepatoma H22 cells [J]. Chin Pharmacol Bull,1996, 12 (1): 71-73.
[15] Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening [J]. J Natl Cancer Inst, 1990, 82: 1170-1112.
[16] Carmichael J, DeGraff Gazdar AF. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity [J]. Cancer Res, 1987, 47 (4): 936.
[17] Cheng S, Peng XM. Technology of Biomedical and Electron Microscopy [M]. Beijing: BeijingMedical University Publishing House, 1997, 104.
[18] Takeda K, Minowade J, Bloch A. Kinetics of appearance of differentiation-associated characteristics in ML-1, a line of human myeloblastic leukemia cells, after treatment with 12-O-tetradecanoylphorbol-13-acetate, dimethyl sulfoxide, or 1-β-D-arabinofuranosylcytosine [J]. Cancer Res, 1982, 42 (12): 5152-5158.
[19] Andrzei V. Regulation of acid phosphatase activity in human promyelocytic leukemia cells induced to differentiate in culture [J]. J Cell Biol, 1979, 83: 300-307.
[20] Shen H, Guan CF. Development of an ELISA method for determination of protein tyrosine kinase activity [J]. Chin J Immunol, 1997, 13 (6): 354.
[21] Cummings J, Langdon SP, Ritchie AA, et al. Pharmacokinetics, metabolism and tumor disposition of 8-Cl-cAMP in breast cancer patients and xenograft-bearing mice [J]. Annu Oncol, 1996, 7: 291-296.
[22] Juranic Z, Radulovic S, Joksimovic J, et al. The mechanism of 8-Cl-cAMP action [J]. J Exp Clin Cancer Res, 1998, 17: 269-275.
[23] Adrian M, Senderowicz, Edward AS. Preclinical and clinical development of cyclin-dependent kinase modulators [J]. J Natl Cancer Inst, 2000, 92 (5): 376-387.